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ABSTRACT 
 
Background: Genistein (GEN), a naturally occurring flavonoid present in soy bean, has 
attracted scientific interest for its possible benefits in cancer. Objective: The potential 
immunomodulatory effects of genistein on the immune system and against TC-1 tumor 
cell line were evaluated in adult female C57BL/6 mice. Methods: Mice were treated 
with GEN 10 days before to 10 days after the tumor induction. Thirty days after the last 
GEN treatment, lymphocyte proliferation, Lactase Dehydrogenase (LDH) cytolytic 
activity and cytokine secretion were analyzed in GEN and control groups. Results: The 
results showed that ingestion of genistein significantly increased lymphocyte 
proliferation and LDH release. Furthermore, the treatment with genistein also caused a 
significant increment in interferon gamma (IFN-γ). In addition, the treatment achieved 
significant therapeutic effect in tumor models compared to the control group. These 
results indicated that the effect of GEN on tumor growth may be attributed to its effect 
on lymphocyte proliferation, cytolytic activity and IFN-γ production. Conclusion: 
These results demonstrate that GEN exerts an immunomodulatory effect in a mouse 
model of Human Papillomavirus (HPV) associated-cervical cancer. 
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INTRODUCTION 
 
Human papillomavirus (HPV) has been identified as the etiological agent of cervical 
carcinoma, the second most common malignancy in women worldwide. Moreover, 
HPVs are suspected to be also involved in the induction of other tumors, and the 
development of treatment against HPV remains of utmost priority (1). Chemoprevention 
is an important strategy to control the process of carcinogenesis. The potential of using 
medicinal herbs as cancer chemopreventive nutraceuticals and functional foods is 
promising. Thus, there is a need for exploring drugs/agents which act as 
chemopreventive agents. 
Genistein (GEN) (4, 7, 4′-trihydroxyisoflavone) is a phytoestrogen found in high levels 
in soy bean products (2). Phytostrogens comprise a family of biologically active plant 
agents called isoflavones, possessing an estrogenic effect (3). 
GEN-containing dietary supplements and soy bean food ingestion has been linked 
through epidemiological studies, with a range of potential health effects. These include 
prevention of breast, colon, and prostate cancers and cardiovascular disease (4-5). The 
potential beneficial effects of GEN in the human population are supported by similar 
findings in experimental animals (6).  
Although GEN has been shown to inhibit cancer cell growth by inhibiting the activity of 
some enzymes in vitro, this effect of GEN has not been associated with an antitumor 
effect in vivo (7). 
One possible mechanism for GEN to prevent tumor development may involve its effect 
on the immune system and the modulation of the immune response (8). In contrast, it 
has been shown that GEN has phytosteroid and estrogen-like activity. Therefore, there 
has been concern that the estrogenic effects of these compounds might have side effects 
in some situations (9). Due to controversial reports on chemopreventive potential of 
genistein, the antitumor and immune induced responses of genistein in HPV-associated 
tumor was investigated in this study. 
 
 
MATERIALS AND METHODS 
 
Mice and Cells. C57BL/6 mice (6–8 weeks old) were purchased from the Pasteur 
Institute (Karaj, Iran). Mice were housed for 1 week before the experiment, given free 
access to food and water, and maintained in a light/dark cycle with lights on from 6: 00 
to 18: 00 h. All experiments were done according to the guidelines for the care and use 
and the guidelines of the laboratory animal ethical commission of shefa neuroscience 
research center. 
TC-1, (Part of the Johns Hopkins Special Collection) was derived from primary 
epithelial cells of C57BL/6 mice cotransformed with HPV16 E6 and E7 and activated c-
Ha-ras oncogene. TC-1 cell line which is HPV-16 E7+ was used as a tumor model in an 
H-2b murine system.TC-1 cell line was grown in Roswell Park Memorial Institute 
medium (RPMI 1640) (Gibco-BRL) supplemented with 10% (v/v) fetal calf serum 
(FCS), penicillin/ streptomycin 50 U/ml, 2 mM glutamine, 1 mM sodium pyruvate, 
2mM nonessential amino acids, and G418 0.4 mg/ml at 37°C with 5% CO2. 
Tumor Therapy Assay. For in vivo tumor experiments, C57BL/6 mice (ten per group) 
were challenged by subcutaneous injection in the right flank with 2×105 TC-1 cells 
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suspended in 100 µl PBS. PBS- treated mice were used as background control group in 
all experiments. 
Experimental Design. Mice were separated in three experimental groups. The mice 
were gavaged daily with genistein (20 mg/kg) (LC laboratories, USA) dissolved in 4% 
DMSO (Sigma Aldrich, USA) (Group 1-test group), 4% DMSO (Group 2-Vehicle 
control). For healthy control group, the mice were mock-infected and PBS-treated 
(Group 3). All the treatments were done 10 days before to 10 days after the tumor 
induction. 
Subcutaneous tumor volume was estimated according to Carlsson’s formula (11); 
hence, the largest (a) and the smallest (b) superficial diameters of the tumor were 
measured twice a week and then the volume (V) of the tumor was calculated by the 
formula: 
(V=a× b×
 
 
) 
 
Statistical analysis was performed using Student’s t test. All values were expressed as 
means ± S.D. 
Lymphocyte Proliferation Assay (LPA). For assessing lymphocyte proliferation, LPA 
test was performed. Twenty four hours after the last gavage, spleens from the 
immunized mice were removed and red blood cells were cleared by incubation in lysis 
buffer (0.15 M  NH4Cl, 1 mM KHCO3, 0.1 mM Na2EDTA, pH 7.2) for 5 min at 37 C. 
Obtained mononuclear cells (2x105 cells/well) were grown in each 96-well plate (Nunc, 
Denmark).The preparations were cultured with RPMI-1640 supplemented with 10% 
fetal calf serum, 1% L-glutamine, 1% HEPES, 0.1% 2ME, 0.1% penicillin/streptomycin 
and induced in the presence of 10 µg/ml genistein. T cell mitogen PHA 
(phytohemaglutenin, Sigma chemicals) at a concentration of 5 µg/ml was used as a 
positive control. Unstimulated splenocytes were used as a negative control. After 3 
days, MTT (3-(4,5-dimethyl tetrazolyl-2) 2,5 diphenyl) tetrazolyumbromide (Sigma 
chemicals) in a concentration of 5 µg/ml was added per well and incubated for 5 h at 
37C in 5% CO2. DMSO (dimethyl sulfoxide) (100 µl) was added to dissolve the 
formazan crystals produced. 
Plates were read at 540 nm, and the results were expressed as stimulation index (SI). 
The SI was determined as follows: OD values of stimulated cells (Cs) minus the relative 
cell number of the unstimulated cells (Cu) multiplied or divided by relative OD values 
of unstimulated cells. All tests were performed in triplicate for each mouse. 
Cell Cytotoxicity Assay. In order to assess cell cytotoxicity, lactate dehydrogenase 
(LDH) level was determined in splenocytes. Twenty-four hours after the final 
administration, mice were sacrificed and their splenocytes were isolated. For each 
sample obtained from individual mouse, single cell suspension of mononuclear cells 
(used as the effecter cells) were cocultured in RPMI 1640 medium with washed EL4 
target cells at various effector-to-target cell ratios (E/T ratios) for 4h in phenol red-free 
RPMI 1640 containing 3% FCS. For preparation of the target cells, EL-4 cells were 
stimulated with genistein antigen (5 µg/ml).  
After centrifugation, the supernatants (50 µl/well) were transferred to the 96-well flat-
bottom plates, and lysis of target cells were determined by measuring LDH release 
using Cytotoxicity Detection Kit (LDH) according to the procedures stated by the 
manufacturer (Takara Company). Several controls were used for the cytotoxicity assay. 
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“High control” was the total LDH released from the target cells, and all EL4 cells were 
lysed by a medium containing 1% Triton X-100. “Low control” was the natural release 
of LDH from the target cells which was obtained by adding only EL4 cells in the assay 
medium. “T-cell control” was used to measure the natural release of LDH from T cells, 
obtained by only adding the different ratios of T cells in the assay medium. The assay 
for all samples, including the controls, was performed in triplicate (10). 
The LDH-mediated conversion of the tetrazolium salt into red formazan product was 
measured at 490 nm after incubation at room temperature for 30 min. The percentage of 
specific cytolysis was determined by the following formula: 
 
 
% Cytotoxicity =  [(experimental value − effector cell control) −  
low control
high control − low control
] × 100 
 
 
Cytokine Assay. Twenty- four hours after the last oral administration, mice were 
sacrificed and their splenocytes were isolated.  
Mononuclear cells from spleens of immunized mice at a concentration of 2×106 
cells/well were incubated in 24-well plates (Nunc, Denmark) for 2 days in a total 
volume of 1.5 ml of RPMI-1640 supplemented with 10% FCS, 1% L-glutamine, 1% 
HEPES, 0.1% 2ME, 0.1% penicillin/streptomycin and pulsed with 10 µg/ml genistein. 
The cell supernatants were collected and assayed for the presence of cytokines using 
commercially available sandwich-based ELISA kits (eBioscience, USA) following 
manufacturer’s instruction. All tests were performed in triplicate for each mouse. 
Data Analysis. To compare results among different groups, one way analysis of 
variance (ANOVA) with scheffe post hoc comparison was performed. SPSS statistical 
software version 11.0 was utilized for statistical analyses. Differences were considered 
statistically significant when p values were <0.05. 
 
 
RESULTS 
 
Lymphocyte Proliferation Response. In order to evaluate the effect of GEN treatment 
on the proliferation of T lymphocytes, three mice per group were used for this 
experiment. The mice were gavaged daily with GEN or DMSO. The animals were 
sacrificed and the spleen cells were harvested. The lymphocytes were activated in vitro 
by GEN and evaluated by MTT methods. A significant increase (p<0.01) in the 
lymphocyte proliferation was evident in GEN treated groups over those of negative control 
ones, following stimulation of the spleen cells with antigen, as shown in Figure 1. 
In order to assess the effect of GEN on the lactate dehydrogenase release, 3 mice/group 
were used. E/T ratio of 50:1 demonstrated the most significant results among different 
groups and was selected for further analysis. As shown in Figure 2, lymphocytes in 
immunized mice with GEN (29.4 ± 1.2%) increased specific cytolytic activity at an E/T 
ratio of 50:1 significantly as compared to that of DMSO (vehicle control) group (18.5 ± 
1.9%) or the healthy control group (13.5 ± 2.9) (p<0.01). 
However, no statistically significant difference in cytolytic activity was found between 
the DMSO (vehicle control) group and the healthy control group (p>0.05).  
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The most significant difference among all these groups was at an E/T ratio of 50:1 (data 
not shown). Based on the results, the CTL activities in immunized mice with GEN 
group was stronger than those in the control ones. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Splenocyte proliferation levels after in vitro stimulation with GEN antigen. C57BL/6 
mice were challenged by subcutaneous injection of TC-1 cells. Twenty-four hours after final 
immunization, spleens of mice (three per group) were removed and lymphocyte proliferation 
was evaluated with MTT method. Formazan crystal formation after incubation of MTT was 
determined by solving the crystals in DMSO and optical density (OD) was read at 540 nm. 
Values are mean ± standard error of the mean for the experiments. Lymphocyte proliferation of 
GEN group was significantly higher than those in control ones (p≤0.01).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. CTL assays to demonstrate lymphocytes in mice vaccinated with GEN using 
quantitative measurement of LDH release assay. After mice were immunized with GEN for 20 
days, spleens were harvested as described in Materials and Methods. Data were collected from 
LDH results at various E/T ratios (E/T=25:1, 50:1, 100:1) and expressed as cytotoxicity 
percentage ± SD. Data shown here are from three independent experiments performed in 
triplicate (p<0.01). 
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Cytokine Assay. To determine whether treatment with GEN could modulate cytokine 
secretion and increase specific immune responses, we measured IL-4 and IFN-γ levels 
in the supernatants of mononuclear cells from treated mice re-stimulated in vitro with 
GEN antigen. ELISA results obtained from culture supernatants harvested at 72 h 
showed that, in response to GEN, spleen cells from the GEN group produced higher 
level of T helper cell type 1 (Th1)-associated cytokine IFN-γ and lower level of the T 
helper cell type 2 (Th2)-associated cytokine IL-4 (p<0.001), compared to the control 
groups, as shown in Figure 3. The results indicate that GEN regimen predominantly 
displays a Th1 cytokine profile. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. Determination of the production of IFN-γ and IL-4 cytokines. Collected supernatants 
were screened for the presence of IFN-γ and IL-4 to determine the type (Th1 versus Th2) of the 
immune response. Concentration of cytokines was determined by comparison to a standard 
curve of serially diluted positive control samples. The data is represented as mean ± S.D. Each 
sample was examined in triplicate and results are representative of two experiments (p< 00.05). 
 
 
 
Tumor Protection. To determine whether the observed enhancement in the number of 
GEN-specific cellular immune responses after treatment with GEN could be correlated 
to a GEN-specific anti-tumor effect, we performed an in vivo tumor treatment 
experiment using a previously characterized E7-expressing tumor model, TC-1 (11).  
Mice were injected with 2×105 TC-1 cells/mouse subcutaneously on the right flank, and 
then gavaged daily with GEN from 10 days before to 10 days after the tumor induction. 
Tumors were measured twice a week once they became palpable. Controls consisted of 
vehicle control group mice challenged with tumors. The tumor volume was monitored 
up to 30 days after the last GEN treatment (10 days after tumor induction).  
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As shown in figure 4, mice treated with GEN significantly reduced both tumor growth 
(as measured by volume) and tumor weights when compared to the control mice 
(p<0.05). These results indicate that vaccination with GEN could induce therapeutic 
anti-tumor effects.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4. Therapeutic vaccination against TC-1-induced tumors. Mice were inoculated with 
2×10
5 TC-1 tumor into the right flank and were monitored for the evidence of tumor growth by 
palpation and inspection twice a week up to 30 days after the last GEN treatment. For the 
determination of tumor volume, each individual tumor size was measured. Line and scatter plot 
graphs depicting the tumor volume (mm
3
) are presented. The data presented is a representative 
of two independent experiments. 
 
 
DISCUSSION 
 
Immune system plays an important role in protection against tumor growth. Cytotoxic T 
lymphocytes constitute the major antitumor effector population against tumor growth 
and dissemination (10,12). Consistent with the reported chemopreventive effect of 
GEN, the present study demonstrated that administration of GEN by gavage for 20 days 
at physiologically relevant doses in adult female C57BL/6 mice significantly increased 
antitumor and immune modulating effects to TC-1 tumor cells in vivo models. 
For evaluating the GEN antitumor responses, we examined its effects on different 
aspects of immune response using three immunoassay experiments, including LDH 
cytotoxicity test, interferon-γ and lymphocyte proliferation assay. Cytotoxicity and 
lymphocyte proliferation assays were carried out to test the specific cellular immune 
response generated by genistein treatment. The capacity to elicit an effective T cell 
immunity can be shown by the stimulation of lymphocyte proliferation response. 
Interferon-γ assay was carried out to examine whether the immune response to TC-1 
tumor was in a cell-mediated pathway or not. Interferon-γ is a cytokine involved in cell 
mediated immune response, especially for Cytotoxic T cells and TH1 cells (13). Primed 
T cells usually respond quickly and strongly when they come in contact with antigens 
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that they have previously encountered. In the present paper, we demonstrated that GEN 
administration stimulates Cytotoxic T lymphocytes, T cell immunity and interferon 
gamma responses compared to controls.  
Consistent with the tumor inhibitory effect of GEN reported in humans, increased 
resistance against cervical cancer was observed after exposure of mice to GEN by 
gavage for 20 d. This is also in agreement with previous studies that oral administration 
of GEN inhibited B16F10 lung-tumor nodule formation (14) and decreased B16 tumor 
volume (15).  In another study, Gue et al. showed that at dosages of 6 and 20 mg/kg for 
28 d by gavage, GEN significantly decreased B16F10 lung tumor nodule formation 
(16). In the present study, we used 20 mg/kg GEN for 20 days by gavage based on 
previous studies which have shown that this dose induces maximum 
immunomodulation in the mice (16). 
There are several possible mechanisms that may be responsible for the inhibitory effect 
of GEN on cervical cancer tumor growth. Some in vitro studies have demonstrated that 
GEN can directly inhibit the proliferation of tumor cells (17). However, these 
mechanisms may not play an important role in our in vivo tumor model.  
In general agreement with previous in vivo studies, our results confirm that the chemo-
preventive effects of GEN may be related to its immunomodulatory effects. 
Immunomodulatory effects of GEN have been shown in previous studies. Gue et al. 
demonstrated significantly increased activities of cytotoxic T cells (CTLs) and natural 
killer cells by GEN in C57BL/6 mice. The authors conclude that the effect of GEN on 
CD4+CD25+ regulatory T cells might be responsible in part for its stimulatory effect on 
T cells (18). In line with these findings, our results show increased CTL and 
lymphocyte proliferation responses. 
Another study showed that the oral administration of 20 mg/kg genistein increased IFN-
γ from T cells in response to ovalbumin in female DO11.10 mice. In contrast to the 
female mice, genistein did not increase cytokine production in male mice, suggesting 
that the effect of genistein on cytokine production is gender-dependent (19). 
Accordingly, our present findings verify that GEN treatment induces the increased 
secretion of IFN-γ from the T cells of GEN- treated female mice.  
One of the important mechanisms by which GEN exerts its immune response effect is to 
interact with Estrogen Receptors (ERs) and compete with estrogen for binding (20). 
ERα is required for 17 β-estradiol-induced increases in IFN-γ expression and Th1 
responses. It is possible that binding of GEN to ERβ would leave more free 17 β-
estradiol to interact with ERα, thus enhancing T cell activity (21).The main constituent 
responsible for the immunomodulatory effect of genistein is an isoflavone (4, 7, 4-
trihydroxyisoflavone) (22).  
These results suggest that orally administrated GEN exerts its immunomodulatory 
effects in female mouse model of cervical cancer in part by increasing proliferation of 
splenic lymphocytes, elevating cytolytic activity and IFN-γ production, thereby 
inducing protective anti-tumor immunity. In conclusion, GEN simulates and modulates 
the immune response to a desired level against HPV-16 tumor-bearing mice. 
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